Drug Profile
CPGJ 602
Alternative Names: CPGJ602; Recombinant human-mouse chimeric anti-EGFR monoclonal antibody - Sunshine GuojianLatest Information Update: 05 Jul 2022
Price :
$50
*
At a glance
- Originator Sunshine Guojian Pharmaceutical
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 29 Jun 2022 Safety and efficacy data from a phase II trial in Colorectal cancer (First-line therapy, In adults, In the elderly, Metastatic disease, Combination therapy, Inoperable/unresectable) presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
- 10 Jul 2020 Sunshine Guojian Pharmaceutical plans a phase II trial in Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease, Inoperable/unresectable) (IV) (NCT04466254)